Compare General Motors Company (GM) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs IDEXX Laboratories, Inc. — how do they compare? General Motors Company trades at $87.28 (market cap $78.40B), while IDEXX Laboratories, Inc. trades at $571.83 (market cap $46.22B). The key difference: General Motors Company is the larger of the two by market cap, and General Motors Company pays a 0.81% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| GM | IDXX | |
|---|---|---|
Market Cap | $78.40B | $46.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $766.68 |
52-Week Low | $54.16 | $526.44 |
Enterprise Value | $181.38B | $47.12B |
Dividend Yield | 0.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $87.74, down 0.25% on the day, with strong technical momentum indicated by bullish moving averages. The company has demonstrated consistent earnings outperformance, beating estimates in the last three quarters. Recent strategic moves include a $4.5 billion parts supply deal and extending its China joint venture for 20 years. Valuation metrics show attractive P/S and P/B ratios, though profitability margins remain thin with net income margin at 1.05%.
GM presents a compelling investment case with analyst consensus pointing to 24% upside to the $108.82 price target. Strong cash flow generation and strategic partnerships support growth prospects, but investors face risks from declining profit margins, rising debt levels, and automotive industry cyclicality. The stock's current technical positioning near key support levels suggests potential for near-term stability.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
